Predictors of disease course in patients with acute myocarditis

Circulation

Volumn 102, Issue 23, 2000, Pages 2829-2835

  Fuse, K ^a   Kodama, M ^a   Okura, Y ^a   Ito, M ^a   Hirono, S ^a   Kato, K ^a   Hanawa, H ^a   Aizawa, Y ^a  

^a NIIGATA UNIVERSITY   (Japan)

Author keywords

Fas; Myocarditis; Prognosis

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEART HEMODYNAMICS; HUMAN; MALE; MYOCARDITIS; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL;

EID: 0034610446     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.102.23.2829     Document Type: Article

References (33)

1. Viral myocarditis: A review
2. Clinicopathologic description of myocarditis
3. Perforin-mediated myocardial damage in acute myocarditis
4. Brief report: Recognition of acute myocarditis masquerading as acute myocardial infarction
5. Clinical outcomes of acute myocarditis in childhood
6. Myocarditis: The Dallas criteria
7. Myocarditis: A histopathologic definition and classification
8. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
9. Increased concentrations of tumor necrosis factor in cachectic patients with severe chronic heart failure
10. Tumor necrosis factor alpha in severe congestive heart failure
11. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure: Relation to nitric oxide-dependent vasodilation in forearm circulation
12. Increased circulating cytokines in patients with myocarditis and cardiomyopathy
13. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure
14. Levels of soluble Fas in patients with myocarditis, heart failure of unknown origin, and in healthy volunteers
15. Levels of soluble Fas ligand in myocarditis
16. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure
17. Serum levels of soluble form of Fas molecule in patients with congestive heart failure
18. Increased circulating soluble form of Fas in patients with dilated cardiomyopathy
19. Elevated circulating levels and cardiac secretion of soluble Fas ligand in patients with congestive heart failure
20. Active myocarditis in the spectrum of acute dilated cardiomyopathies: Clinical features, histologic correlates, and clinical outcome
21. A clinical trial of immunosuppressive therapy for myocarditis: The Myocarditis Treatment Trial Investigators
22. Predictors of adverse outcome in biopsy-proven myocarditis
23. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis
24. Activation of the apoptotic Fas antigen-encoding gene upon influenza virus infection involving spontaneously produced beta-interferon
25. Viral regulation of CD95 expression and apoptosis in T lymphocytes
26. Epstein-Barr virus infects and induces apoptosis in human neutrophils
27. Increased levels of soluble Fas ligand in CSF of rapidly progressive HTLV-1 associated myelopathy/tropical spastic paraparesis patients
28. Expression of apoptosis-related proteins in experimental coxsackievirus myocarditis
29. Apoptosis in congestive heart failure induced by viral myocarditis in mice
30. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
31. Apoptosis by death factor
32. Apoptosis: Basic mechanisms and implications for cardiovascular disease
33. The Fas/Fas ligand system is involved in the pathogenesis of autoimmune myocarditis in rats